Abstract
BackgroundApproximately 250,000 heart valve operations are performed annually worldwide. An intensive research and development effort has led to progressively more advanced heart valve prostheses. The Carpentier-Edwards Perimount Magna Ease (CEPME) prosthesis represents the latest iteration of the Edwards Perimount series of aortic tissue valves. The current study aims to evaluate the midterm performance of this bioprosthesis.MethodsFive hundred and eighteen patients with aortic stenosis underwent aortic valve replacement with the CEPME valve at Papworth Hospital between August 2008 and November 2011. After a minimum of 3 years from the index operation, eligible patients were retrospectively and consecutively recruited to participate. Recruitment was closed after 100 eligible patients had completed all study assessments. Investigations at follow-up included echocardiography, and NYHA status. Primary endpoints included valve performance measures.ResultsThe mean age was 72 years, 64% were male and median follow-up was 5.1 years. NYHA status had improved in 66% of patients. The average postoperative peak and mean pressure gradients decreased by 51.2 mmHg (64.5%) and 31.8 mmHg (59.4%), with a significant improvement in NYHA status. The frequency of moderate aortic regurgitation was 3%. There was no evidence for structural valve deterioration.ConclusionsThe CEPME has excellent mid-term durability. Its use effectively improves haemodynamics and functional capacity.
Highlights
Aortic stenosis is the most common valvular heart disease in Europe and North America [1, 2]
Inclusion criteria were: aortic stenosis or mixed aortic valve disease, implantation of CarpentierEdwards Perimount Magna Ease (CEPME) in the supraannular position, a minimum of 3 years since valve implantation, and isolated aortic valve replacement (AVR) or AVR plus coronary artery bypass grafting in order to obtain a standardised patient cohort
Severe aortic stenosis was defined according to the European Society of Cardiology Valvular Heart Disease guidelines as peak pressure gradient (PPG) > 64 mmHg or mean transvalvular pressure gradients (MPG) > 40 mmHg [13]
Summary
Aortic stenosis is the most common valvular heart disease in Europe and North America [1, 2]. Due to the aging population, approximately 150,000 patients of a total population of 64 million in England are projected to have severe aortic stenosis by 2020 [4]. Once these patients become symptomatic, their mortality rate increases to 25% per year [5, 6]. The 10-year mortality rates among patients with symptomatic aortic stenosis who undergo aortic valve replacement (AVR) approaches the survival rate in the normal population [5, 7]. The current study aims to evaluate the midterm performance of this bioprosthesis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
